US Patent 7582607 Muteins of fibroblast growth factor 21

Patent 7582607 was granted and assigned to Eli Lilly and Company on September, 2009 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

All edits

Edits on 30 May, 2024

"update inverses"

Golden AI

edited on 30 May, 2024

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

‌

US Patent 11993637 Modified FGF-21 polypeptides with non-naturally encoded amino acids

Edits on 17 Sep, 2023

"Add patent inventor(s)"

Golden AI

edited on 17 Sep, 2023

Edits made to:

Infobox (+3 properties)

Infobox

Patent Inventor Names

Christopher Carl Frye0

Lihua Huang0

Radmila Micanovic0

Edits on 16 Sep, 2023

"Add patent abstract"

Golden AI

edited on 16 Sep, 2023

Edits made to:

Article (+503 characters)

Article

Patent abstract

The present invention relates to novel muteins of human fibroblast growth factor 21 with reduced capacity of O-glycosylation when expressed in yeast compared to wild-type human FGF-21. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, or metabolic syndrome.

Edits on 7 Jun, 2023

"update inverses"

Golden AI

edited on 7 Jun, 2023

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

‌

US Patent 11667708 Anti-human beta klotho antibody or binding fragment thereof and methods of their use

Edits on 24 May, 2023

"Remove website redirecting to Patent Public Search front page"